Little information is available on the very elderly patients with diffuse large B-cell lymphoma (DLBCL). We performed a retrospective analysis of 281 patients >80 years old with newly diagnosed DLBCL treated in 4 referral institutions in Switzerland and Northern Italy. Primary end points were overall survival, progression-free survival, and cause-specific survival. Systemic chemotherapy was given to 239 patients, and 119 of them received rituximab in their initial treatment. At a median follow-up of 5.5 years, 5-year progression-free survival was 26% (95% confidence interval [CI], 20-32%), 5-year overall survival was 31% (95% CI, 25-37%), and 5-year cause-specific survival was 48% (95% CI, 41-55%) for the entire cohort. Rituximab and/or anthracyclines as part of initial treatment were associated with improved outcome. Cause-specific survival in patients receiving both agents approximated 60% at 5 years. At multivariate analysis, rituximab use maintained a significant prognostic impact after controlling for age, performance status, stage, haemoglobin, and lactate dehydrogenase levels. The International Prognostic Index as well as the more recently proposed revised-International Prognostic Index and National Comprehensive Cancer Center Network–International Prognostic Index could discriminate patients with significantly different outcomes. Albeit very elderly and potentially frail, there may be a potential for cure in fit DLBCL patients ≥80 years old. Accurate selection of patients able to tolerate proper immunochemotherapy is crucial.

REFERENCES

1Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988; 6(12): 1838-1844.
CAS PubMed Web of Science® Google Scholar
2Mora O, Zucca E. Management of elderly patients with hematological neoplasms. Ann Oncol. 2007; 18(Suppl 1): i49-i53.
10.1093/annonc/mdl451
PubMed Web of Science® Google Scholar
3Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4): 235-242.
10.1056/NEJMoa011795
CAS PubMed Web of Science® Google Scholar
4Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. May 2008; 9(5): 435-444.
10.1016/S1470-2045(08)70078-0
PubMed Web of Science® Google Scholar
5Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12): 2040-2045.
10.1182/blood-2010-03-276246
CAS PubMed Web of Science® Google Scholar
6Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. May 2011; 12(5): 460-468.
10.1016/S1470-2045(11)70069-9
CAS PubMed Web of Science® Google Scholar
7Merli F, Bertini M, Luminari S, et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. Feb 2007; 48(2): 367-373.
10.1080/10428190601078100
PubMed Google Scholar
8Rigacci L, Mappa S, Nassi L, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol. Dec 2007; 25(4): 198-203.
10.1002/hon.827
CAS PubMed Web of Science® Google Scholar
9Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. Jul 2010; 21(7): 1492-1499.
10.1093/annonc/mdp544
CAS PubMed Web of Science® Google Scholar
10Oki Y, Ewer MS, Lenihan DJ, et al. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. Mar 2015; 15(3): 152-158.
10.1016/j.clml.2014.09.001
PubMed Web of Science® Google Scholar
11Zinzani PL, Federico M, Oliva S, et al. The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. Leuk Lymphoma. Jan 2015; 56(1): 12-25.
10.3109/10428194.2014.894187
PubMed Web of Science® Google Scholar
12Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood. 2009; 114(22): 408-408.
Google Scholar
13Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. Apr 2012; 53(4): 581-588.
10.3109/10428194.2011.621565
CAS PubMed Web of Science® Google Scholar
14Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. Apr 2008; 19(4): 774-779.
10.1093/annonc/mdm563
CAS PubMed Web of Science® Google Scholar
15Mounier N, Heutte N, Thieblemont C, et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. Clin Lymphoma Myeloma Leuk. Jun 2012; 12(3): 151-154.
10.1016/j.clml.2011.11.004
PubMed Google Scholar
16Latta S, Cygan PH, Fried W, Nabhan C. Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions. Oncology (Williston Park). 2013; 27(2): 126-130, 132-126, 138.
PubMed Web of Science® Google Scholar
17 A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14): 987-994.
10.1056/NEJM199309303291402
PubMed Web of Science® Google Scholar
18Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5): 1857-1861.
10.1182/blood-2006-08-038257
CAS PubMed Web of Science® Google Scholar
19Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014; 123(6): 837-842.
10.1182/blood-2013-09-524108
CAS PubMed Web of Science® Google Scholar
20Prochazka V, Pytlik R, Janikova A, et al. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS One. 2014; 9(7):e102594.
PubMed Google Scholar
21Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. Oct 2010; 151(2): 143-151.
10.1111/j.1365-2141.2010.08331.x
CAS PubMed Web of Science® Google Scholar
22Melchardt T, Troppan K, Weiss L, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2-microglobulin. Br J Haematol. Jan 2015; 168(2): 239-245.
10.1111/bjh.13116
CAS PubMed Web of Science® Google Scholar
23Olivieri A, Gini G, Bocci C, et al. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist. 2012; 17(5): 663-672.
10.1634/theoncologist.2011-0355
CAS PubMed Web of Science® Google Scholar
24Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012; 17(6): 838-846.
10.1634/theoncologist.2011-0417
CAS PubMed Web of Science® Google Scholar
25Marchesi F, Cenfra N, Altomare L, et al. A retrospective study on 73 elderly patients (>/=75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. Journal of geriatric oncology. Jul 2013; 4(3): 242-248.
10.1016/j.jgo.2013.04.003
PubMed Google Scholar
26Dubruille S, Libert Y, Roos M, et al. Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: major impact of cognition. Journal of geriatric oncology. Sep 2015; 6(5): 362-369.
10.1016/j.jgo.2015.07.006
PubMed Web of Science® Google Scholar
27Morrison VA, Hamlin P, Soubeyran P, et al. Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. Journal of geriatric oncology. Mar 2015; 6(2): 141-152.
10.1016/j.jgo.2014.11.004
PubMed Web of Science® Google Scholar
28Hamaker ME, Augschoell J, Stauder R. Clinical judgement and geriatric assessment for predicting prognosis and chemotherapy completion in older patients with a hematological malignancy. Leuk Lymphoma. Nov 2016; 57(11): 2560-2567.
10.3109/10428194.2016.1163345
PubMed Google Scholar
29Kenis C, Heeren P, Bron D, et al. Multicenter implementation of geriatric assessment in Belgian patients with cancer: a survey on treating physicians' general experiences and expectations. Journal of geriatric oncology. 2014; 5(4): 431-438.
10.1016/j.jgo.2014.06.043
PubMed Google Scholar
30Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (>/=80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. Jan 2012; 156(2): 196-204.
10.1111/j.1365-2141.2011.08934.x
CAS PubMed Web of Science® Google Scholar
31Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604-612.
10.7326/0003-4819-150-9-200905050-00006
PubMed Web of Science® Google Scholar
32Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373-383.
10.1016/0021-9681(87)90171-8
CAS PubMed Google Scholar
33Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol. 1999; 17(4): 1244.
10.1200/JCO.1999.17.4.1244
CAS PubMed Web of Science® Google Scholar
34Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
10.1002/cncr.21979
CAS Web of Science® Google Scholar
35Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187-220.
10.1111/j.2517-6161.1972.tb00899.x
Google Scholar
36Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974; 19(6): 716-723.
10.1109/TAC.1974.1100705
CAS Web of Science® Google Scholar
37Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005; 92(4): 965-970.
10.1093/biomet/92.4.965
Web of Science® Google Scholar
38Bellera C, Praud D, Petit-Moneger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-Pelissier S. Barriers to inclusion of older adults in randomised controlled clinical trials on non-Hodgkin's lymphoma: a systematic review. Cancer Treat Rev. Nov 2013; 39(7): 812-817.
10.1016/j.ctrv.2013.01.007
PubMed Web of Science® Google Scholar
39Coiffier B. When can R-CHOP not be used in an elderly patient? Oncology (Williston Park). 2013; 27(2): 146-148.
PubMed Google Scholar
40Williams JN, Rai A, Lipscomb J, Koff JL, Nastoupil LJ, Flowers CR. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015; 121(11): 1800-1808.
10.1002/cncr.29290
CAS PubMed Web of Science® Google Scholar
41Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010; 116(24): 5103-5110.
10.1182/blood-2010-07-259333
CAS PubMed Web of Science® Google Scholar
42Choi MR, Solid CA, Chia VM, et al. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer. Jun 2014; 22(6): 1619-1628.
10.1007/s00520-014-2121-7
PubMed Google Scholar
43Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, et al. Optimizing the G8 screening tool for older patients with cancer: diagnostic performance and validation of a six-item version. Oncologist. Feb 2016; 21(2): 188-195.
10.1634/theoncologist.2015-0326
PubMed Web of Science® Google Scholar
44Trebouet A, Marchand T, Lemal R, et al. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann Oncol. Oct 2013; 24(10): 2612-2618.
10.1093/annonc/mdt282
PubMed Web of Science® Google Scholar

Citing Literature

Volume36, Issue1

February 2018

Pages 84-92

Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Abstract

REFERENCES

Citing Literature

References

Related

Information